"These interim results (of a phase II study) suggest GS101 eye drops to be an effective and safe approach to specifically inhibit and regress active corneal neovascularization, a major risk factor for corneal graft rejection", indicated Professor Claus Cursiefen, of the Department of Ophthalmology, Friedrich Alexander University, in Germany.
"Compared to the placebo group with 100% ongoing progression of corneal neovascularisation over the 3-month period, the optimal treatment group achieved 86% regression and progression in only 14%", he added.
Prof. Cursiefen will take advantage of the world's largest gathering for ophthalmologists, the Annual Meeting of the American Association of Ophtalmologist in Atlanta, USA, on November 8 - 11, 2008, to present these promising results.
In parallel, Gene Signal is developing a diverse pipeline of novel antisense oligonucleotides, proteins and monoclonal antibodies to treat a range of angiogenesis based diseases. It is evaluating three new drugs in ophthalmology as well as in dermatology and is in the discovery phase with four more molecules addressing indications in the field of vascular disease and oncology.
About Gene Signal
Gene Signal (http://www.genesignal.com) is a biotechnology company
focused on discovering genes involved in the regulation of angiogenesis.
Founded in 2000, the company has assembled an outstanding leadership team
that includes scientific, medical, regulatory, and business professionals
with successful track records in developing and bringing to market state of
the art drugs. Gene Signal continues to develop its angiogenesis modulating
technology and has built a significant intellectual property portfolio, as
|SOURCE Gene Signal International SA|
Copyright©2008 PR Newswire.
All rights reserved